Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 14;11:1399. doi: 10.1038/s41598-021-80999-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

SHP2 inhibition displays combination benefit with PD1 blockade. (a) Tumor growth curve (expressed as tumor volume) of subcutaneous CT26 tumors in CT26 syngeneic mice with different treatments. TNO155: 20 mg/kg, PO, BID; Anti-PD1: 10 mg/kg, IP, QW. (b, c) Tumor growth curve (expressed as tumor volume) of subcutaneous MC38 tumors in MC38 syngeneic mice with different treatments. Mice were treated with Vehicle + IgG, anti-PD1, TNO155 and TNO155 + anti-PD1 in (b); Mice were treated with Vehicle + IgG, anti-PD1, SHP099 and SHP099 + anti-PD1 in (c); TNO155: 20 mg/kg, PO, BID; SHP099: 100 mg/kg, PO, QD; Anti-PD1: 10 mg/kg, IP, QW. (d) Flow cytometry analysis of the percentage of CD8+ T cells over CD45+ immune cells in MC-38 syngeneic model. (e) Flow cytometry analysis of the percentage of CD11b+ myeloid cells over CD45+ cells in MC-38 syngeneic model. (f) Flow cytometry analysis of the percentage of gMDSCs over CD45+ cells in MC-38 syngeneic model. (g) Flow cytometry analysis of the percentage of mMDSCs over CD45+ cells in MC-38 syngeneic model. (h) Flow cytometry analysis of the percentage ratio of M1 macrophage over M2 macrophage in MC-38 syngeneic model. Flow cytometry data was analyzed and processed with FlowJo (Version 10.7.1, https://www.flowjo.com/solutions/flowjo/downloads/previous-versions).